Abstract Uracil in DNA is an important cause of mutagenesis. SMUG1 is a uracil-DNA glycosylase that removes uracil through base excision repair. SMUG1 also processes radiation-induced oxidative base damage as well as 5-fluorouracil incorporated into DNA during chemotherapy. We investigated SMUG1 mRNA expression in 249 primary breast cancers. SMUG1 protein expression was investigated in 1,165 breast tumours randomised into two cohorts [training set (n = 583) and test set (n = 582)]. SMUG1 and chemotherapy response was also investigated in a series of 315 ERnegative tumours (n = 315). For mechanistic insights, SMUG1 was correlated to biomarkers of aggressive phenotype, DNA repair, cell cycle and apoptosis. Low SMUG1 mRNA expression was associated with adverse disease specific survival (p = 0.008) and disease-free survival (p \ 0.0001) were likely in low SMUG1 tumours. Low SMUG1 protein expression was associated with poor prognosis in univariate (p \ 0.001) and multivariate analysis (p \ 0.01). In ER? cohort that received adjuvant endocrine therapy, low SMUG1 protein expression remains associated with poor survival (p \ 0.01). In ER-cohort that received adjuvant chemotherapy, low SMUG1 protein expression is associated with improved survival (p = 0.043). Our study suggests that low SMUG1 expression may correlate to adverse clinicopathological features and predict response to adjuvant therapy in breast cancer.
Introduction
Uracil in DNA is an important cause of mutagenesis and may result either from incorporation of dUMP during replication leading to U:A mismatches, spontaneous generation or by enzymatic deamination of cytosine leading to U:G mismatches. Unrepaired U:G mismatches are 100 % mutagenic leading to G:C to A:T transition mutations that are frequently seen in human tumours [1] . Uracil-DNA repair is essential to protect against mutagenicity and this is accomplished by the DNA base excision repair (BER) machinery. Uracil BER is initiated by uracil-DNA glycosylases. UNG2 and SMUG1 are important uracil-DNA glycosylases that process uracil in DNA [1] .
Emerging data suggest a role for SMUG1 in carcinogenesis. Smug1 was shown to be an important uracil-DNA glycosylase in Ung-deficient mice [2] . In Msh2(-/-) mice, loss of Smug1 as well as Ung increases cancer predisposition [3] . In addition, a tenfold increase in spontaneous C:G to T:A transitions has been observed in cells deficient in Smug1 and Ung [4] . Smug1 and Ung-deficient cells were also hypersensitive to ionising radiation in that study [4] . A recent study has also demonstrated that in premenopausal women, SMUG1 rs2029166 genotype may increase breast cancer risk in those with low folate intake [5] .
SMUG1 as well as UNG may also be essential for excising 5-fluorouracil (5-FU) incorporated into the DNA during chemotherapy. Although Smug1 knockdown was shown to result in accumulation of 5-FU [6] , the study however, did not take into consideration possible differences in growth rate or pool perturbation of nucleotide pool sizes. In a recent study, loss of UNG did not affect 5-FU sensitivity but loss of SMUG1 led to twofold increase in sensitivity to 24 h treatment of 5-FU followed by recovery. In cell exposed to continuous 5-FU, however, no difference was observed in Smug1 depleted cells. Upon 5-FU treatment, SMUG1-depleted cells did show a prolonged S-phase arrest and a transient increase in DNA doublestrand breaks in that study [7] . Similarly, the role of Ung in 5-FU sensitivity has also been described in cell lines [8, 9] . SMUG1 is also a key enzyme for repairing 5-hydroxymethyluracil, 5-formyluracil, 5,6-dihydrouracil, alloxan and other lesions generated during oxidative base damage induced by ionising radiation and oxygen free radicals [4] . Removal of uracil in BER creates an abasic site (AP site) which is processed further by several enzymes including human AP endonuclease (APE1), poly (ADP-ribose) polymerase 1 (PARP1), DNA polymerase b and DNA ligase III-XRCC1 heterodimer which completes the repair process [10] . A recent study has also suggested a role for smug1 in RNA metabolism [11] implying additional functions for SMUG1.
Given the emerging role of SMUG1 in the maintenance of genomic integrity, we hypothesised that SMUG1 may be dysregulated in breast cancer. In the current study, we have investigated SMUG1 mRNA and protein expression in primary operable breast cancers and have demonstrated for the first time that SMUG1 deficiency may be linked to aggressive clinical phenotype and also predicts response to therapy.
Materials and methods

Study population
Uppsala cohort for SMUG1 mRNA expression
The Uppsala cohort originally composed of 315 women representing 65 % of all breast cancers resected in Uppsala County, Sweden, from January 1, 1987, to December 31, 1989 . Demographics are summarised in supplementary Table  S1 of supporting information and also described elsewhere [12] . Tumour samples were microarray profiled on the Affymetrix U133A&B genechips. Microarray analysis was carried out at the Genome Institute of Singapore. All microarray data are accessible at National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (http://www. ncbi.nlm.nih.gov/geo/). Data can be accessed via series accession number (GSE4922). RNA preparation, microarray hybridization and data processing were carried out essentially as described [13] . All data were normalised using the global mean method (MAS5), and probe set signal intensities were natural log transformed and scaled by adjusting the mean signal to a target value of log 500.
Nottingham cohort for SMUG1 protein expression
The study was performed in a consecutive series of patients with primary invasive breast carcinomas who were diagnosed between 1986 and 1999 and entered into the Nottingham Tenovus Primary Breast Carcinoma series. A series of 1,165 primary operable breast cancers were available. Patients were randomised into two equal cohorts by use of a double random number sort. Alternate cases were put into a training set (583 tumours) and a test set (583 tumours). All patients were treated uniformly in a single institution and have been investigated in a wide range of biomarker studies [14] [15] [16] . Supplemental Table  S2 summarises patient demographics. Both cohorts were well balanced with regards to clinicopathological features, treatment and survival data. Patients received standard surgery (mastectomy or wide local excision) with radiotherapy. Prior to 1989, patients did not receive systemic adjuvant treatment (AT). After 1989, AT was scheduled based on prognostic and predictive factor status, including Nottingham Prognostic Index (NPI), oestrogen receptor-a (ER-a) status and menopausal status. Patients with NPI scores of \3.4 (low risk) did not receive AT. Premenopausal patients with NPI scores of C3.4 (high risk) were given classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy; patients with ER-a positive tumours were also offered hormone therapy (HT). Postmenopausal patients with NPI scores of C3.4 and ER-a positivity were offered HT, while ER-a negative patients received classical CMF chemotherapy. Median follow-up was 111 months (range 1-233 months). Survival data, including overall survival, disease-free survival (DFS) and development of loco-regional and distant metastases (DM), was maintained on a prospective basis. DFS was defined as the number of months from diagnosis to the occurrence of local recurrence, local lymph node (LN) relapse or DM relapse. Breast cancer-specific survival (BCSS) was defined as the number of months from diagnosis to the occurrence of BC related-death. Local recurrence-free survival (LRS) was defined the number of months from diagnosis to the occurrence of local recurrence. DM-free survival was defined as the number of months from diagnosis to the occurrence of DM relapse. Survival was censored if the patient was still alive at the time of analysis, lost to follow-up, or died from other causes.
We also evaluated a cohort of 315 ER-a negative invasive BCs. Demographic and treatment characteristics of this cohort are summarised in supplementary Table  S3 .
The Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) criteria, recommended by McShane et al. [17] , were followed throughout this study. This work was approved by Nottingham Research Ethics Committee.
Tissue microarrays (TMAs) and immunohistochemistry (IHC)
Tumours were arrayed in tissue microarrays (TMAs) constructed with two replicate 0.6 mm cores from the centre and periphery of the tumours. The TMAs were immunohistochemically profiled for SMUG1 and other biological antibodies [ER, PR, AR, Her-2, CK5/6, CK14, EGFR, ATM, BRCA1, XRCC1, P27, P21, MIB1, Bax, BCL-2, p 53, MDM2 and MDM4 as previously described [18] [19] [20] [21] (primary antibodies, clone, source, optimal dilution and scoring system used for each immunohistochemical (IHC) marker is summarised in supplementary Table S4)]. IHC staining for SMUG1 was performed using the Bond Max automated staining machine and Leica Bond Refine Detection kit (DS9800) according to manufacturer instructions (Leica Microsystems). TMAs sections were incubated for 15 min at room temperature with 1/200 goat anti-SMUG1 monoclonal antibody (Acris Antibody GmbH). Pre-treatment of TMA section was performed with citrate buffer (pH 6.0) for 20 min. HER2 expression was assessed according to the new ASCO/CAP guidelines using IHC and fluorescence in situ hybridisation (FISH) [22] .
Evaluation of immune staining
We utilised H-score method as well as quick score method for SMUG1 nuclear staining analysis in tumours. For Hscore assessment, whole field inspection of the core was performed and intensities of nuclear staining were grouped as follows: 0 = no staining, 1 = weak staining, 2 = moderate staining, 3 = strong staining. The percentage of staining in each category was estimated (0-100 %). Hscore (range 0-300) was calculated by multiplying intensity of staining by percentage staining as previously described [18] [19] [20] [21] . Low SMUG1 (SMUG1-) expression was defined by mean H-score B35.
For quick score, the intensity and proportion of cells staining for SMUG1 was analysed. Proportion of staining was scored as follows: 0 (negative), 1 (B1 %), 2 (1-10 %), 3 (11-33 %), 4 (34-66 %) and 5 ([66-100 %). Intensity of staining was scored as follows: 1 (weak), 2 (moderate) and 3 (strong). The two scores were added to give a quick score in the range 0-8 (by definition, there is no quick score of 1) [19] . Low SMUG1 (SMUG1-) expression was defined by Quick score \4 which was equivalent to H-score B35. Not all cores within the TMA were suitable for IHC analysis due to missing cores or absence of tumour cells.
Cancer cell lines and culture
In addition to the breast cancer cell lines (MCF-7, MDA-MB-231, MDA-MB-436), we also investigated colon cancer cell lines (Colo-205, C-170), gastric cancer cell lines (AGS, ST-16) and pancreatic cancer cell lines (Panc1, ASPC-1) for SMUG1 protein expression. The cell lines were purchased from ATCC and grown in RPMI medium supplemented with 10 % FBS, 1 % penicillin/streptomycin.
Western blot analysis
This assay was performed as described previously [23] . Primary antibodies used was an anti-SMUG1 goat polyclonal antibody (catalogue no: AP08884PU-N, Acris Antibody GmbH, Germany). The secondary antibody was a HRP-conjugated secondary anti-goat (Dako, Glostrup, Denmark) antibody. As well as cell extracts from the cell lines, recombinant GST-tagged SMUG1 protein (Novus biological, USA) was simultaneously used as a positive control and to investigate the specificity of anti-SMUG1 antibody.
Statistical analysis
Data analysis was performed using SPSS (SPSS, version 17 Chicago, IL, USA). Where appropriate, Pearson's v 2 , Fisher's exact, Student's t and ANOVA one-way tests were used. Cumulative survival probabilities were estimated using the Kaplan-Meier method, and differences between survival rates were tested for significance using the logrank test. Multivariate analysis for survival was performed Breast Cancer Res Treat (2013) 142:515-527 517 using the Cox proportional hazard model. The proportional hazards assumption was tested using standard log-log plots. Hazard ratio (HR) and 95 % confidence intervals (95 % CI) were estimated for each variable. All tests were two-sided with a 95 % CI and a p value \0.05 considered significant. For multiple comparisons, p values were adjusted according to Holm-Bonferroni correction method [24] .
Results
Low SMUG1 transcript levels correlate to poor survival
We first evaluated SMUG1 mRNA expression in 249 breast cancers comprising the Uppsala cohort. 50.6 % of tumours had high SMUG1 mRNA levels and 49.4 % of tumours had low SMUG1 mRNA expression levels. Low SMUG1 mRNA expression in tumours was associated with adverse disease specific survival (p = 0.008) (Fig. 1a) and DFS (p = 0.008) (Fig. 1b) in patients.
We then proceeded to investigate SMUG1 protein expression in breast cancer.
Low SMUG1 protein expression is linked to aggressive phenotype
We evaluated specificity of SMUG1 antibody by western blot analysis. In addition to the breast cancer cell lines (MCF-7, MDA-MB-231, MDA-MB-436), we also investigated colon cancer cell lines (Colo-205, C-170), gastric cancer cell lines (AGS, ST-16) and pancreatic cancer cell lines (Panc1, ASPC-1) for SMUG1 protein expression.
Recombinant SMUG1 protein was used as a positive control. Figure 2a demonstrates robust SMUG1 protein expression across a panel of cancer cell lines. The anti-SMUG1 antibody that specifically binds recombinant SMUG1 protein was used as a positive control and provides evidence for the specificity of the antibody. In addition, Fig. 2b demonstrates more than twofold reduction in SMUG1 expression in MDA-MB-436 cells compared to MCF-7 cells providing evidence of differential expression of SMUG1 across breast cancer cell lines. We then proceeded to conduct IHC evaluation of SMUG1 protein expression in human breast cancers. We first investigated in a training set and then validated in a test set of breast cancer cohorts.
Training set (n = 583) 145/583 (25 %) of the tumours were low for SMUG1 expression, and 439/583 (75 %) tumours were high for SMUG1 expression (Fig. 2c) . Low SMUG1 expression was highly significantly associated with adverse pathological features (Table 1) Low SMUG1 expression was significantly associated with loss of expression of BRCA1 (p \ 0.0001), ATM (p \ 0.0001) and XRCC1 (p \ 0.0001). Loss of p27 and p21 expression was more common in low SMUG1 tumours (p \ 0.0001 and p = 0.023 respectively). High MIB1 was significantly associated with low SMUG1 expression (p \ 0.0001). Low SMUG1 expression was also significantly associated with low expression of p53 downstream genes that regulate cell cycle progression and apoptosis such as MDM2 (p = 0.016), MDM4 (p = 0.0003), Bcl2 (p \ 0.0001) and Bax (p = 0.008).
Low SMUG1 expression is associated with adverse clinical outcome at 10 years, with a significant increase in the risk of death (p \ 0.0001) (Fig. 2g) and recurrence (p = 0.005) (Fig. 2e ) compared with high SMUG1 tumours. Low SMUG1 ER? breast cancers receiving adjuvant endocrine therapy had poor survival (p = 0.023) and a trend to increase recurrence (p = 0.099) compared to patients with high SMUG1 tumours (Fig. 3a, b) .
In multivariate Cox regression analysis including other validated prognostic factors (such as LN stage, histological grade and tumour size), low SMUG1 was an independent predictor for breast cancer-specific survival (p = 0.018) as well as DFS (p = 0.031) ( Table 3) .
Test set (n = 582) 138/582 (24 %) of the tumours were low for SMUG1 expression, and 444/582 (76 %) tumours were high for SMUG1 expression. Low SMUG1 expression was highly significantly associated with adverse pathological features ( Table 2) including larger tumours (p = 0.009), high histological grade (p \ 0.0001), high mitotic index (p \ 0.0001), pleomorphism (p \ 0.0001) and glandular de-differentiation (p = 0.0042). In addition, low SMUG1 expression was also significantly linked to aggressive features such as absence of hormonal receptors (ER-/PgR-/ AR) (p \ 0.0001), EGFR over expression (p = 0.002), HER-2 overexpression (p = 0.038), presence of basal-like phenotype (p \ 0.0001) and triple-negative phenotype (p \ 0.0001) ( Table 2) .
Low SMUG1 expression was significantly associated with loss of expression of BRCA1 (p = 0.01), ATM (p = 0.002) and XRCC1 (p \ 0.0001). Loss of p27 was more common in low SMUG1 tumours (p \ 0.0001). High MIB1 was significantly associated with low SMUG1 tumours (p \ 0.0001). Low SMUG1 expression was also significantly associated with mutant p53 (p = 0.037) as well as low expression of p53 downstream genes that regulate cell cycle progression and apoptosis such as MDM2 (p \ 0.0001), MDM4 (p = 0.004), Bcl2 (p = 0.001) and Bax (p = 0.003).
Low SMUG1 expression is associated with adverse clinical outcomes at 10 years with a significant increase in the risk of death (p \ 0.0001) (Fig. 2f) and recurrence (p = 0.006) (Fig. 2g ) compared with SMUG1 high tumours. Low SMUG1 ER? breast cancers receiving adjuvant endocrine therapy had poor survival (p = 0.003) and increased recurrence (p = 0.016) compared to patients with SMUG1 high tumours (Fig. 3c, d) .
In multivariate Cox regression analysis including other validated prognostic factors (such as LN stage, histological grade and tumour size), low SMUG1 expression was an independent predictor for breast cancer-specific survival (p = 0.027) as well as DFS (p = 0.034) ( Table 3) .
Clinicopathological significance in ER-negative breast cancers (n = 315) 77/315 (24 %) of the tumours were low for SMUG1 expression, and 238/315 (76 %) tumours were high for SMUG1 expression. Low SMUG1 expression was significantly associated with high vascular invasion (p = 0.01) and triple-negative phenotype (p = 0.003) ( Table 4 ). Her-2 over expression (p = 0.001) and LN positive disease (p = 0.008) was more likely in SMUG1 high tumours. Low SMUG1 expression was more likely to be associated with XRCC1 loss in this cohort. In ER-patients who received chemotherapy, high SMUG1 expression was associated with twofold increase in risk of death (p = 0.043) and recurrence (p = 0.043) indicating resistance to chemotherapy (Fig. 3e, f) .
Discussion
Impaired DNA repair may increase mutation rate, enhance chromosomal instability and promote selection of more malignant clones with aggressive behaviour [25, 26] . SMUG1 uracil-DNA glycosylase may be an anti-mutator protein involved in BER [2] . Besides a role in genomic integrity, a recent study has also suggested a critical role for SMUG1 in RNA metabolism [11] . This is the first study to evaluate SMUG1 expression in breast cancer. We provide the first evidence that low SMUG1 expression in breast tumours is associated with an aggressive phenotype such as high histological grade, pleomorphism, glandular de-differentiation, absence of hormonal receptors and presence of basal-like and triple-negative phenotypes. Low SMUG1 expression is also associated with loss of expression of BRCA1, ATM and XRCC1, implying genomic instability in SMUG1 low tumours. Moreover, association with abnormal expression of p53, p27, MDM2, MDM4, Bcl-2 and Bax provides additional evidence for higher level of genomic instability in SMUG1 low tumours. Low SMUG1 expression was associated with poor survival in univariate as well as multivariate analysis in both the training and test set that predominantly consisted of ER? tumours (80 %). In ER? tumours that received endocrine therapy, in particular, low SMUG1 expression is also associated with poor survival indicating that SMUG1 status may predict endocrine response, although the mechanism for resistance is unknown. On the other hand, in ER-tumours that received chemotherapy, low SMUG1 expression is associated with better survival indicating sensitivity to chemotherapy. The clinical data presented in ER-tumours are consistent with preclinical studies where SMUG1 depletion has been shown to result in sensitivity to 5-FU chemotherapy [6, 27] . In a recent study in 112 gastric cancers, we found that SMUG1 high tumours were associated with adverse clinical outcome such as poor DFS (p = 0.02) and disease specific survival (p = 0.05) [28] . The data in gastric cancer is in contrast to that presented in breast tumours in the current study. We speculate that low SMUG1 expression in breast cancer may increase genomic instability and promote a cancerous phenotype. On the other hand, in gastric cancer, where inflammation is driver for carcinogenesis, up-regulation of BER may be required to repair oxidative base damage that is commonly seen in an inflammatory environment. SMUG1 up-regulation in this context could promote cancer survival and resistance to therapy. Taken together, the data suggests that SMUG1 may have complex roles in carcinogenesis and larger studies in multiple tumour types are required to clarify further the role of SMUG1 in cancer. A limitation to our study is that it is retrospective. Although we have demonstrated that low SMUG1 is associated with an aggressive phenotype, we have not directly shown that SMUG1 loss results in a mutator phenotype in breast cancer. Aggressive tumours are highly proliferative and it is possible that SMUG1 down-regulation in highly proliferative tissue may have no causal relation to the aggressive phenotype. Future mechanistic preclinical studies could clarify whether SMUG1 loss confers a mutator phenotype in breast cancer.
The link between DNA repair, ER, p53 and its downstream targets MDM2 and p21 in breast cancer are beginning to emerge [29] . Although the regulation of uracil-DNA glycosylases is largely unknown, recent studies suggest a potential role for p53. For example, thymine-DNA glycosylase (TDG) that belongs to the superfamily of uracil-DNA glycosylases has been shown to be transcriptionally regulated by p53 [30] . Moreover, PPM1D, a p53-induced oncogenic phosphatase has been shown to interact with uracil-DNA glycosylase (UNG2) and suppress BER [31] . Interestingly, p73, a member of p53 family, may be directly involved in transcriptional regulation of SMUG1 [32] . Whether p53 is also involved in SMUG1 regulation remains unknown. In addition, NFI/CTF transcription factor has also been shown to be involved in SMUG1 regulation [33] implying that SMUG1 regulation may be complex in cells.
We recently investigated XRCC1, another key BER protein in breast cancer [23] . As seen in SMUG1, loss of XRCC1 (16 %) was also associated with high grade (p \ 0.0001), loss of hormone receptors (p \ 0.0001), triple negative (p \ 0.0001) and basal-like phenotypes (p = 0.001). Loss of XRCC1 was associated with a twofold increase in risk of death (p \ 0.0001) and independently with poor outcome (p \ 0.0001). We also demonstrated a novel synthetic lethality application using DNA double-strand break repair inhibitors in XRCC1 deficient breast cancer cells [23] . Taken together, our data suggests that BER deficiency in breast tumours contribute to aggressive clinical behaviour and could be targeted for personalised treatment strategy in patients.
